Cited by 148Schizophrenia research and treatmentAmino Acid Enzymes and MetabolismTryptophan and brain disorders

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial

Kantrowitz, Joshua T, Woods, Scott W, Petkova, Eva, Cornblatt, Barbara, Corcoran, Cheryl M, Chen, Huaihou, Silipo, Gail, Javitt, Daniel C·2015·The Lancet Psychiatry

DOI 10.1016/s2215-0366(15)00098-x

Open this paper in CoChat — free account

Abstract

Background Antagonists of N-methyl-D-aspartate-type glutamate receptors (NMDAR) induce symptoms that closely resemble those of schizophrenia, including negative symptoms. D-serine is a naturally occurring NMDAR modulator that reverses the effects of NMDAR antagonists in animal models of schizophrenia. D-serine effects have been assessed previously for treatment of established schizophrenia, but not in the early stages of the disorder. We aimed to assess effects of D-serine on negative symptoms in at risk individuals.Methods We did a double-blind, placebo-controlled, parallel-group randomised clinical trial at four academic US centres. Individuals were eligible for inclusion in the study if they were at clinical high risk of schizophrenia, aged between 13-35 years, had a total score of more than 20 on the Scale of Prodromal Symptoms (SOPS), and had an interest in participation in the clinical trial. Exclusion criteria included a history of suprathreshold psychosis symptoms (ie, no longer qualifying as prodromal) or clinical judgment that the reported symptoms from the SOPS were accounted for better by another disorder (eg, depression). Randomisation was done using a generated list with block sizes of four. Participants were stratified by site, with participants, investigators, and assessors all masked through use of identical looking placebos and centralised drug dispensation to study assignment. D-serine (60 mg/kg) was given orally in divided daily doses for 16 weeks. The primary endpoint was for negative SOPS, measured weekly for the first 6 weeks, then every 2 weeks. Participants who received at least one post-baseline assessment were included in analysis. Serum cytokine concentrations were collected at baseline, midpoint, and endpoint to assess the mechanism of action. Safety outcomes including laboratory assessments were obtained for all individuals. This trial is registered with ClinicalTrials.gov, number NCT0082620.Findings We enrolled participants between April 2, 2009, and July 23, 2012. 44 participants were randomly assigned to receive either D-serine (n=20) or placebo (n=24); 35 had assessable data (15 D-serine, 20 placebo). D-serine induced a 35·7% (SD 17·8) improvement in negative symptoms, which was significant compared with placebo (mean final SOPS negative score 7·6 [SEM 1·4] for D-serine group vs 11·3 [1·2] for placebo group; d=0·68, p=0·03). Five participants who received D-serine and nine participants who received placebo discontinued the study early because of withdrawn consent or loss to follow-up (n=8), conversion to psychosis (n=2), laboratory-confirmed adverse events (n=2), or protocol deviations (n=2).Interpretation This study supports use of NMDAR-based interventions, such as D-serine, for treatment of prodromal symptoms of schizophrenia. On the basis of observed effect sizes, future studies with sample sizes of about 40 per treatment group would be needed for confirmation of beneficial effects on symptoms and NMDAR-related inflammatory changes. Long-term studies are needed to assess effects on psychosis conversion in individuals at clinical high risk of schizophrenia.Funding National Institutes of Health.

Integrity signals

Registry

Crossref · 10.1016/s2215-0366(15)00098-x

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,603
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,417
Estimating the Dimension of a Model
Schwarz, G. (1978) · The Annals of Statistics · doi:10.1214/aos/1176344136 · Cited by 47,033
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Self-citation
Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment
Khandaker, G. M., Cousins, L., Deakin, J., Lennox, B. R., Yolken, R., & Jones, P. B. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00122-9 · Cited by 926
Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial
Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.192 · Cited by 896
D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chang, Y., & Chong, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 676

Show all 62 references

Sorted by citations

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
Altering the course of schizophrenia: progress and perspectives
Millan, M. J., Andrieux, A., Bartzokis, G., Cadenhead, K., Dazzan, P., Fusar-Poli, P., Gallinat, J., Giedd, J., Grayson, D. R., Heinrichs, M., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.28 · Cited by 516
Auditory dysfunction in schizophrenia: integrating clinical and basic features
Javitt, D. C., & Sweet, R. A. (2015) · Nature reviews. Neuroscience · doi:10.1038/nrn4002 · Cited by 377
Self-citation
Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis
Hardingham, G. E., & Do, K. Q. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.19 · Cited by 304
The NMDA Receptor and Schizophrenia
Balu, D. T. (2016) · Advances in pharmacology · doi:10.1016/bs.apha.2016.01.006 · Cited by 303
Detection and analysis of chiral molecules as disease biomarkers
Liu, Y., Wu, Z., Armstrong, D. W., Wolosker, H., & Zheng, Y. (2023) · Nature Reviews Chemistry · doi:10.1038/s41570-023-00476-z · Cited by 261
Lack of evidence to favor specific preventive interventions in psychosis: a network meta‐analysis
Davies, C., Cipriani, A., Ioannidis, J. P. A., Radua, J., Stahl, D., Provenzani, U., McGuire, P., & Fusar‐Poli, P. (2018) · World Psychiatry · doi:10.1002/wps.20526 · Cited by 229
Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions
Miller, B. J., & Goldsmith, D. R. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.211 · Cited by 182
Treating Negative Symptoms in Schizophrenia: an Update
Remington, G. J., Foussias, G., Fervaha, G., Agid, O., Takeuchi, H., Lee, J., & Hahn, M. (2016) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-016-0075-8 · Cited by 167
Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality
Lieberman, J. A., Small, S. A., & Girgis, R. R. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19080865 · Cited by 165
Glutamatergic dysfunction in Schizophrenia
Kruse, A. O., & Bustillo, J. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02253-w · Cited by 162
Preventive interventions for individuals at ultra high risk for psychosis: An updated and extended meta-analysis
Mei, C., van der Gaag, M., Nelson, B., Smit, F., Yuen, H. P., Berger, M., Krcmar, M., French, P., Amminger, G. P., Bechdolf, A., et al. (2021) · Clinical Psychology Review · doi:10.1016/j.cpr.2021.102005 · Cited by 143
Caught in vicious circles: a perspective on dynamic feed-forward loops driving oxidative stress in schizophrenia
Cuénod, M., Steullet, P., Cabungcal, J.-H., Dwir, D., Khadimallah, I., Klauser, P., Conus, P., & Kim, Q. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01374-w · Cited by 134
D-Serine: Potential Therapeutic Agent and/or Biomarker in Schizophrenia and Depression?
MacKay, M.-A. B., Kravtsenyuk, M., Thomas, R. K., Mitchell, N., Dursun, S. M., & Baker, G. B. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00025 · Cited by 128
Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms
Kantrowitz, J. T., Epstein, M. L., Lee, M., Lehrfeld, N., Nolan, K. A., Shope, C., Petkova, E., Silipo, G., & Javitt, D. C. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.02.027 · Cited by 123
Self-citation
Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine
Kantrowitz, J. T., Epstein, M. L., Beggel, O., Rohrig, S. N., Lehrfeld, J. M., Revheim, N., Lehrfeld, N., Reep, J., Parker, E. M., Silipo, G. S., et al. (2016) · Brain · doi:10.1093/brain/aww262 · Cited by 115
Self-citation
Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence)
Fusar-Poli, P., Davies, C., Solmi, M., Brondino, N., De Micheli, A., Kotlicka-Antczak, M., Shin, J. I., & Radua, J. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00764 · Cited by 108
Efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis: A network meta-analysis
Davies, C., Radua, J., Cipriani, A., Stahl, D., Provenzani, U., McGuire, P., & Fusar-Poli, P. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00187 · Cited by 107
Interventions for prodromal stage of psychosis
Kuharić, D. B., Kekin, I., Hew, J., Kuzman, M. R., & Puljak, L. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012236.pub2 · Cited by 116
D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures
Foster, A. C., Farnsworth, J. C., Lind, G. E., Li, Y.-X., Yang, J., Dang, V., Penjwini, M., Viswanath, V., Staubli, U. V., & Kavanaugh, M. P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156551 · Cited by 90
N-Acetyl-Aspartyl-Glutamate in Brain Health and Disease
Morland, C., & Nordengen, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031268 · Cited by 89
Progress and Future Directions in Research on the Psychosis Prodrome
Woodberry, K. A., Shapiro, D. I., Bryant, C., & Seidman, L. J. (2016) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000109 · Cited by 87
Low d-serine levels in schizophrenia: A systematic review and meta-analysis
Cho, S., Na, K., Cho, S.-J., & Kang, S. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.10.006 · Cited by 83
Negative Symptom Interventions in Youth at Risk of Psychosis: A Systematic Review and Network Meta-analysis
Devoe, D. J. A., Peterson, A. M., & Addington, J. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx139 · Cited by 82
Early Identification and Intervention of Schizophrenia: Insight From Hypotheses of Glutamate Dysfunction and Oxidative Stress
Lin, C., & Lane, H. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00093 · Cited by 85
Attenuated psychotic symptom interventions in youth at risk of psychosis: A systematic review and meta‐analysis
Devoe, D. J. A., Farris, M. S., Townes, P., & Addington, J. (2018) · Early Intervention in Psychiatry · doi:10.1111/eip.12677 · Cited by 86
Sleep disturbances in individuals at clinical high risk for psychosis
Poe, S.-L., Brucato, G., Bruno, N., Arndt, L. Y., Ben-David, S., Gill, K. E., Colibazzi, T., Kantrowitz, J. T., Corcoran, C. M., & Girgis, R. R. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2016.12.029 · Cited by 75
Self-citation
The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review
Girgis, R. R., Zoghbi, A. W., Javitt, D. C., & Lieberman, J. A. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.07.006 · Cited by 75
Self-citation
Changes in serum TNF-α, IL-18, and IL-6 concentrations in patients with chronic schizophrenia at admission and at discharge
Luo, Y., He, H., Zhang, J., Ou, Y., & Fan, N. (2019) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2019.01.003 · Cited by 70
d-Amino acids and kidney diseases
Kimura, T., Hesaka, A., & Isaka, Y. (2020) · Clinical and Experimental Nephrology · doi:10.1007/s10157-020-01862-3 · Cited by 70
The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders
Peyrovian, B., Rosenblat, J. D., Pan, Z., Iacobucci, M., Brietzke, E. M., & McIntyre, R. S. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.02.001 · Cited by 76
Advances in D-Amino Acids in Neurological Research
Seckler, J. M., & Lewis, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197325 · Cited by 71
Astrocytic Regulation of Glutamate Transmission in Schizophrenia
Mei, Y.-Y., Wu, D., & Zhou, N. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00544 · Cited by 67
Inflammatory biomarkers in individuals at clinical high risk for psychosis (CHR-P): State or trait?
Khoury, R., & Nasrallah, H. A. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.04.017 · Cited by 65
Potential and Challenges for the Clinical Use of d-Serine As a Cognitive Enhancer
Guercio, G. D., & Panizzutti, R. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00014 · Cited by 67
New discoveries for an old drug: a review of recent olanzapine research
Meftah, A. M., Deckler, E., Citrome, L., & Kantrowitz, J. T. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1701823 · Cited by 69
Self-citation
The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia
Uliana, D. L., Lisboa, J. R., Gomes, F. V., & Grace, A. A. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116298 · Cited by 71
Progression from being at-risk to psychosis: next steps
Addington, J., Farris, M. S., Devoe, D. J. A., & Metzak, P. D. (2020) · Schizophrenia · doi:10.1038/s41537-020-00117-0 · Cited by 59
N -Methyl-D-Aspartate (NMDA) receptor modulators: a patent review (2015-present)
Ahmed, H., Haider, A., & Ametamey, S. M. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1811234 · Cited by 59
Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation
Wolf, G., Singh, S., Blakolmer, K., Lerer, L. B., Lifschytz, T., Heresco‐Levy, U., Lotan, A., & Lerer, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01832-z · Cited by 51
Enhancing NMDA Receptor Function: Recent Progress on Allosteric Modulators
Yao, L., & Zhou, Q. (2017) · Neural Plasticity · doi:10.1155/2017/2875904 · Cited by 50
Mismatch negativity: A simple and useful biomarker of N-methyl-d-aspartate receptor (NMDAR)-type glutamate dysfunction in schizophrenia
Avissar, M., & Javitt, D. C. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.11.006 · Cited by 45
Self-citation
Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans
Thiebes, S., Leicht, G., Ćurić, S., Steinmann, S., Polomac, N., Andreou, C., Eichler, I., Eichler, L., Zöllner, C., Gallinat, J., et al. (2017) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.160187 · Cited by 43
Intervention strategies for ultra-high risk for psychosis: Progress in delaying the onset and reducing the impact of first-episode psychosis
McGorry, P. D., Mei, C., Hartmann, J., Yung, A. R., & Nelson, B. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.12.026 · Cited by 49
Prediction and Prevention in the Clinical High-Risk for Psychosis Paradigm: A Review of the Current Status and Recommendations for Future Directions of Inquiry
Worthington, M., & Cannon, T. D. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.770774 · Cited by 47
Managing Negative Symptoms of Schizophrenia: How Far Have We Come?
Kantrowitz, J. T. (2017) · CNS Drugs · doi:10.1007/s40263-017-0428-x · Cited by 46
Self-citation
Cross Cultural Validation and Extension of the Clinical Assessment Interview for Negative Symptoms (CAINS) in the Chinese Context: Evidence from a Spectrum Perspective
Xie, D., Shi, H., Lui, S. S. Y., Shi, C., Li, Y., Ho, K. K. Y., Hung, K. S. Y., Li, W., Yi, Z., Cheung, E. F. C., et al. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby013 · Cited by 43
The interhemispheric miscommunication theory of auditory verbal hallucinations in schizophrenia
Steinmann, S., Leicht, G., & Mulert, C. (2019) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2019.02.002 · Cited by 44
Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients With Schizophrenia
Pei, J.-C., Luo, D.-Z., Gau, S.-S., Chang, C., & Lai, W. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.742058 · Cited by 48
Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics
de Bartolomeis, A., Vellucci, L., Austin, M. C., Simone, G. D., & Barone, A. (2022) · Biomolecules · doi:10.3390/biom12070909 · Cited by 43
N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophrenia
Kantrowitz, J. T. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.02.003 · Cited by 40
Self-citation
Chronic d-serine supplementation impairs insulin secretion
Suwandhi, L., Hausmann, S., Braun, A., Gruber, T., Heinzmann, S. S., Gálvez, E. J. C., Buck, A., Legutko, B., Israel, A., Feuchtinger, A., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.07.002 · Cited by 41
Neurophysiological Effects of Bitopertin in Schizophrenia
Kantrowitz, J. T., Nolan, K. A., Epstein, M. L., Lehrfeld, N., Shope, C. B., Petkova, E., & Javitt, D. C. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000722 · Cited by 40
Self-citation
A tale of two sites: Differential impairment of frequency and duration mismatch negativity across a primarily inpatient versus a primarily outpatient site in schizophrenia
Lee, M., Sehatpour, P., Dias, E. C., Silipo, G. S., Kantrowitz, J. T., Martı́nez, A., & Javitt, D. C. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.07.032 · Cited by 40
Self-citation
Ethical and Epidemiological Dimensions of Labeling Psychosis Risk
Corcoran, C. M. (2016) · The AMA Journal of Ethic · doi:10.1001/journalofethics.2016.18.6.msoc2-1606 · Cited by 40
Self-citation
Supplementation with D-serine prevents the onset of cognitive deficits in adult offspring after maternal immune activation
Fujita, Y., Ishima, T., & Hashimoto, K. (2016) · Scientific Reports · doi:10.1038/srep37261 · Cited by 39
Modulating NMDA Receptor Function with d-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model
Sershen, H. W., Hashim, A., Dunlop, D. S., Suckow, R. F., Cooper, T. B., & Javitt, D. C. (2016) · Neurochemical Research · doi:10.1007/s11064-016-1838-8 · Cited by 38
Self-citation
The impact of inflammation on neurocognition and risk for psychosis: a critical review
Kogan, S., Ospina, L. H., Mittal, V. A., & Kimhy, D. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01073-2 · Cited by 38
D-Serine: A Cross Species Review of Safety
Meftah, A. M., Hasegawa, H., & Kantrowitz, J. T. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.726365 · Cited by 43
Self-citation
Luvadaxistat: A Novel Potent and Selective d-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia
Fradley, R. L., Goetghebeur, P., Miller, D., Burley, R., Almond, S., Gruart, A., García, J. M. D., Zhu, B., Howley, E., Neill, J. C., et al. (2023) · Neurochemical Research · doi:10.1007/s11064-023-03956-2 · Cited by 36
L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial
Ghajar, A., Khoaie-Ardakani, M.-R., Shahmoradi, Z., Alavi, A.-R., Afarideh, M., Shalbafan, M., Ghazizadeh‐Hashemi, M., & Akhondzadeh, S. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.02.012 · Cited by 35
Multidisciplinary Treatment for Individuals at Clinical High Risk of Developing Psychosis
Addington, J., Devoe, D. J. A., & Santesteban‐Echarri, O. (2019) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-019-0164-6 · Cited by 33
Attrition rates in trials for adolescents and young adults at clinical high‐risk for psychosis: A systematic review and meta‐analysis
Farris, M. S., Devoe, D. J. A., & Addington, J. (2019) · Early Intervention in Psychiatry · doi:10.1111/eip.12864 · Cited by 37
Localized Detection of d ‐Serine by using an Enzymatic Amperometric Biosensor and Scanning Electrochemical Microscopy
Polcari, D., Perry, S. C., Pollegioni, L., Geißler, M., & Mauzeroll, J. (2017) · ChemElectroChem · doi:10.1002/celc.201600766 · Cited by 29
Competitive Inhibitors Unveil Structure/Function Relationships in Human D-Amino Acid Oxidase
Molla, G. (2017) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2017.00080 · Cited by 29
Towards a neurodynamical understanding of the prodrome in schizophrenia
Mikanmaa, E., Grent-‘t-Jong, T., Hua, L., Recasens, M., Thuné, H., & Uhlhaas, P. J. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.11.026 · Cited by 33
Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia
Koola, M. M., Praharaj, S. K., & Pillai, A. (2019) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-019-00174-5 · Cited by 27
Validation and extension of the Motivation and Pleasure Scale-Self Report (MAP-SR) across the schizophrenia spectrum in the Chinese context
Wang, L., Eugenia, P., Lui, S. S. Y., Cheung, E. F. C., Cheng, K., & Chan, R. C. K. (2020) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2020.101971 · Cited by 27
Phenylglycine analogs are inhibitors of the neutral amino acid transporters ASCT1 and ASCT2 and enhance NMDA receptor-mediated LTP in rat visual cortex slices
Foster, A. C., Rangel-Diaz, N., Staubli, U. V., Yang, J., Penjwini, M., Viswanath, V., & Li, Y. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.010 · Cited by 27
Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways
Zhang, T., Liu, C., Zhong, N., Wang, Y., Huang, Y., & Zhang, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910668 · Cited by 26
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia
Schaefer, M., Sarkar, S., Theophil, I., Leopold, K., Heinz, A., & Gallinat, J. (2019) · Pharmacopsychiatry · doi:10.1055/a-0970-9310 · Cited by 25
Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia
Wu, Q., Huang, J., & Wu, R. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.641047 · Cited by 24
The Role of D-Serine and D-Aspartate in the Pathogenesis and Therapy of Treatment-Resistant Schizophrenia
Nasyrova, R., Khasanova, A. K., Altynbekov, K. S., Asadullin, A., Markina, E. A., Gayduk, A., Shipulin, G., Petrova, M. M., & Shnayder, N. (2022) · Nutrients · doi:10.3390/nu14235142 · Cited by 16
Relationship of serum levels of TNF-α, IL-6 and IL-18 and schizophrenia-like symptoms in chronic ketamine abusers
Fan, N., Luo, Y., Xu, K., Zhang, M., Ke, X., Huang, X., Ding, Y., Wang, D., Ning, Y., Deng, X., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.11.006 · Cited by 21
The association between polyunsaturated fatty acid consumption and the transition to psychosis in ultra-high risk individuals
Pawełczyk, T., Trafalska, E., Kotlicka‐Antczak, M., & Pawełczyk, A. M. (2016) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2016.03.010 · Cited by 22
Transition to psychosis in randomized clinical trials of individuals at clinical high risk of psychosis compared to observational cohorts: a systematic review and meta-analysis
de Pablo, G. S., Davies, C., Ruiz, H. D. D., Solmi, M., Shin, J. I., Carvalho, A. F., Raduà, J., & Fusar‐Poli, P. (2021) · European Psychiatry · doi:10.1192/j.eurpsy.2021.2222 · Cited by 20
Early Intervention and a Direction of Novel Therapeutics for the Improvement of Functional Outcomes in Schizophrenia: A Selective Review
Kurachi, M., Takahashi, T., Sumiyoshi, T., Uehara, T., & Suzuki, M. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00039 · Cited by 21
Evaluation of variability in individual response to treatments in the clinical high-risk state for psychosis: A meta-analysis
Raduà, J., Davies, C., & Fusar‐Poli, P. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.05.010 · Cited by 20
l-Arginine metabolism before and after 10 weeks of antipsychotic treatment in first-episode psychotic patients
Garip, B., Kayır, H., & Uzun, Ö. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.12.015 · Cited by 21
Aberrant hierarchical prediction errors are associated with transition to psychosis: A computational single-trial analysis of the mismatch negativity
Hauke, D. J., Charlton, C. E., Schmidt, A., Griffiths, J., Woods, S. W., Ford, J. M., Srihari, V. H., Roth, V., Diaconescu, A. O., & Mathalon, D. H. (2022) · doi:10.1101/2022.12.20.22283712 · Cited by 18
Self-citation
Enhancing Electrochemical Biosensor Selectivity with Engineered d -Amino Acid Oxidase Enzymes for d -Serine and d -Alanine Quantification
Moussa, S., Murtas, G., Pollegioni, L., & Mauzeroll, J. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00409 · Cited by 18
A polymorphism in the glutamate metabotropic receptor 7 is associated with cognitive deficits in the early phases of psychosis
Chaumette, B., Sengupta, S. M., Lepage, M., MALLA, A. K., Iyer, S. N., Kébir, O., Dion, P. A., Rouleau, G. A., Krebs, M., Shah, J. L., et al. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.06.019 · Cited by 18
Antipsychotic prescription, assumption and conversion to psychosis: resolving missing clinical links to optimize prevention through precision
Zhang, T., Raballo, A., Zeng, J., Gan, R., Wu, G., Wei, Y., Xu, L., Tang, X., Hu, Y., Tang, Y., et al. (2022) · Schizophrenia · doi:10.1038/s41537-022-00254-8 · Cited by 18
Spirulina platensis reduces the schizophrenic-like symptoms in rat model by restoring altered APO-E and RTN-4 protein expression in prefrontal cortex
Haider, S., Shahzad, S., Batool, Z., Sadir, S., Liaquat, L., Tabassum, S., & Perveen, T. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119417 · Cited by 19
Glutamate modulators for treatment of schizophrenia
Zhand, N., Attwood, D. G., & Harvey, P. D. (2019) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2019.02.001 · Cited by 16
Biotypes in Psychosis: Has the RDoC Era Arrived?
Javitt, D. C. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16020140 · Cited by 15
Self-citation
Early Detection and Prevention of Schizophrenic Psychosis—A Review
Westhoff, M. S., Ladwig, J., Heck, J., Schülke, R., Groh, A., Deest, M., Bleich, S., Frieling, H., & Jahn, K. (2021) · Brain Sciences · doi:10.3390/brainsci12010011 · Cited by 14
Connecting Neurobiological Features with Interregional Dysconnectivity in Social-Cognitive Impairments of Schizophrenia
Adraoui, F. W., Douw, L., Martens, G. J. M., & Maas, D. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097680 · Cited by 14
The Time Sequence of Gene Expression Changes after Spinal Cord Injury
Mun, S., Han, K., & Hyun, J. K. (2022) · Cells · doi:10.3390/cells11142236 · Cited by 16
Neuronal serine racemase associates with Disrupted-In-Schizophrenia-1 and DISC1 agglomerates: Implications for schizophrenia
Jacobi, A. A., Halawani, S. M., Lynch, D. R., & Lin, H. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.10.055 · Cited by 12
Network Meta-Analysis Indicates Superior Effects of Omega-3 Polyunsaturated Fatty Acids in Preventing the Transition to Psychosis in Individuals at Clinical High-Risk
Chen, C., Deng, Y., Li, Y., Zhang, M., Yu, T., Xie, K., Bao, W., Li, P., Sun, L., Zhang, T., et al. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae014 · Cited by 12
Plasma metabolic alterations and potential biomarkers in individuals at clinical high risk for psychosis
Li, Z., Zhang, T., Xu, L., Wei, Y., Cui, H., Tang, Y., Liu, X., Qian, Z., Zhang, H., Liu, P., et al. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.11.011 · Cited by 12
Physiology, Pathophysiology and Clinical Relevance of D‐Amino Acids Dynamics: From Neurochemistry to Pharmacotherapy
Donoso, M. V., Catalán‐Salas, V., Pulgar‐Sepúlveda, R., Eugenín, J. L., & Huidobro-Toro, J. P. (2024) · The Chemical Record · doi:10.1002/tcr.202400013 · Cited by 11
Corticolimbic circuitry as a druggable target in schizophrenia spectrum disorders: a narrative review
Gee, A., Dazzan, P., Grace, A. A., & Modinos, G. (2025) · Translational Psychiatry · doi:10.1038/s41398-024-03221-2 · Cited by 13
Baseline data of a sequential multiple assignment randomized trial (STEP study)
Hartmann, J., Nelson, B., Amminger, G. P., Spark, J., Yuen, H. P., Kerr, M., Polari, A. R., Wallis, N., Blasioli, J., Dixon, L. B., et al. (2022) · Early Intervention in Psychiatry · doi:10.1111/eip.13263 · Cited by 10
Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia
Surti, T. S., Ranganathan, M., Johannesen, J., Gueorguieva, R. V., Deaso, E., Kenney, J. G., Krystal, J. H., & D’Souza, D. C. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.04.010 · Cited by 11
N100 Repetition Suppression Indexes Neuroplastic Defects in Clinical High Risk and Psychotic Youth
Gonzalez–Heydrich, J., Enlow, M. B., D’Angelo, E. J., Seidman, L. J., Gumlak, S., Kim, A., Woodberry, K. A., Rober, A., Tembulkar, S. K., O’Donnell, K., et al. (2016) · Neural Plasticity · doi:10.1155/2016/4209831 · Cited by 12
Multimodal prognosis of negative symptom severity in individuals at increased risk of developing psychosis
Hauke, D. J., Schmidt, A., Studerus, E., Andreou, C., Riecher‐Rössler, A., Raduà, J., Kambeitz, J. P., Ruef, A., Dwyer, D., Kambeitz‐Ilankovic, L., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01409-4 · Cited by 11
Cross species review of the physiological role of d-serine in translationally relevant behaviors
Arizanovska, D., Emodogo, J., Lally, A. P., Palavicino‐Maggio, C. B., Liebl, D. J., & Folorunso, O. O. (2023) · Amino Acids · doi:10.1007/s00726-023-03338-6 · Cited by 9
Bending the curve on psychosis outcomes
Light, G. A., & Swerdlow, N. R. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00172-8 · Cited by 9

Authors: Kantrowitz, J. T., Woods, S. W., Petkova, E., Cornblatt, B., Corcoran, C. M., Chen, H., Silipo, G., & Javitt, D. C.
Affiliations: Nathan Kline Institute for Psychiatric Research (US)
Yale University (US)
Zucker Hillside Hospital (US)
Columbia University (US)
University of Florida (US)
Corresponding author: Javitt, Daniel C
ORCID: Kantrowitz, Joshua T
Woods, Scott W
Petkova, Eva
Cornblatt, Barbara
Corcoran, Cheryl M
Chen, Huaihou
Javitt, Daniel C
Venue: The Lancet Psychiatry
Publisher: Elsevier BV
Published: 2015-05
Volume: 2
Issue: 5
Pages: 403-412
ISSN: 2215-0366 (ISSN-L)
DOI: 10.1016/s2215-0366(15)00098-x
OpenAlex: W2070856797
Cited by: 148
References: 62
Citations by year: 2026: 5 · 2025: 8 · 2024: 7 · 2023: 7 · 2022: 11 · 2021: 19 · 2020: 15 · 2019: 19 · 2018: 17 · 2017: 16 · 2016: 20 · 2015: 4
FWCI: 15.41
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (UL1 TR000040)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords: D-serine, negative symptoms, schizophrenia, clinical high risk, prodromal psychosis, NMDA receptor modulation, serum cytokines, mechanism of action, early intervention
MeSH terms: Adolescent, Adult, Double-Blind Method, Female, Humans, Male, Schizophrenia, Serine, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Risk Assessment, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks